Avantect

? A Story About Pancreatic Cancer by Margaret Freitag We've all read in the news and in the scientific literature that the number of pancreatic cancer cases is increasing even though it's not clear what might be behind that. Among my friends and family, I can count seven people who have been affected by pancreatic cancer - sadly only one survives. Some of them had risk factors like Ashkenazi Jewish heritage, or new onset diabetes. In the case of my friends and family, those risk factors were only recognized in hindsight, and unfortunately all were diagnosed in advanced stages. I know what it's like to survive cancer, albeit not pancreatic. I was diagnosed with a rare cancer with an aggressive histology. I know the angst of waiting for the pathology to come back, for the staging to be confirmed; guessing my chances of making it out to other side. Fortunately, I was diagnosed at an early stage. I powered through surgery, chemotherapy and radiation over the course of nine months. I am grateful to celebrate my five-year survivor anniversary this year. My wishes during pancreatic cancer awareness month are that: ? More patients with pancreatic cancer can have the kind of chance that I had; an earlier diagnosis that allows for an increased chance of survival. ? More patients with risk factors for pancreatic cancer like family history, genetic predisposition and early onset diabetes become aware of these risks and the means for early diagnosis. That’s why I’m grateful to ClearNote Health and the dedicated #pancreaticcancer community in their pursuit of the early diagnosis and successful treatment of pancreatic cancer. #pancreaticcancerday ??

ClearNote Health is attending ISPOR—The Professional Society for Health Economics and Outcomes Research, Nov 17-20, 2024, in Barcelona. ? ClearNote Health’s?Senior Health Economics Consultant,?Adrian Vilalta, PhD, will present findings from a clinico-economic analysis of ClearNote Health’s Avantect Pancreatic Test in a poster entitled “Cell-Free DNA Epigenomic-based Test is Predicted to Be Cost Effective to Manage New-Onset Type 2 Diabetes Patients for Risk of Pancreatic Cancer” (abstract #141003). ? If you are attending the event make sure not to miss his presentation to learn more about how?using the Avantect Pancreatic Cancer Test can be cost effective to manage individuals newly diagnosed with diabetes. #pancreaticcancer

?? Did you know a new diagnosis of type 2 diabetes drastically increases the risk for pancreatic cancer? Learn more about the connection between diabetes and #pancreaticcancer in this short article written by the team at Taking Control Of Your Diabetes (TCOYD) Diabetes. Dr. Steve Edelman, nationally recognized expert in diabetes, discusses the often-unknown connection between a new diagnosis of #type2diabetes and an enhanced risk of pancreatic cancer in the first 36 months post diabetes diagnosis. While just over 1% of patients will be diagnosed with pancreatic cancer, nearly 80% or more of all pancreatic cancer patients have a diabetes diagnosis offering an early sign that can lead to early intervention.? ? ?? Follow this link for the full article:?https://lnkd.in/d4WhnAZR ?? Learn more about the Avantect Pancreatic Cancer Test and ClearNote Health’s story at: https://www.avantect.com/

ClearNote Health is pleased to partner with Dr. Steve Edelman and the team at Taking Control Of Your Diabetes (TCOYD), a provider and patient advocacy group guided by the belief that every person with diabetes has the right to live a healthy, happy and productive life. TCOYD educates and motivates people to take a more active role in their condition by providing education to both medical professionals and patient communities caring for people with #diabetes.

?? Press Release: Avantect Ovarian Cancer Test Receives CPT Code and Preliminary Payment Determination from the Centers for Medicare and Medicaid Services ClearNote Health has today announced the American Medical Association (AMA) has issued a new Current Procedural Terminology (CPT) Proprietary Laboratory Analyses (PLA) code for the Avantect Ovarian Cancer Test. Effective October 1, 2024, the new CPT code, 0507U, establishes a reimbursement pathway for increased patient access and broader test adoption. In addition, CMS announced that it has proposed preliminary reimbursement rate determinations?for new and revised CPT codes issued by the American Medical Association (AMA), including 0507U for the Avantect Ovarian Cancer Detection Test. ClearNote Health aligned with CMS on their reimbursement recommendation of $1,160.00. “Receiving a CPT code and CMS preliminary rate recommendation for our Avantect Ovarian Cancer Test represents the second time ClearNote Health has reached a critical commercial and reimbursement milestone for our organization in less than 12 months, and most importantly, expands patient access to the early detection for ovarian cancer,” said Dave Mullarkey, CEO of ClearNote Health. ?? Read the full press release on our website: https://lnkd.in/d-CyXp-d ?? The Avantect test is intended for patients at high risk for ovarian cancer, such as those with a genetic predisposed risk such as BRCA1, BRCA2, a family history of ovarian cancer, or a personal history of breast cancer before age 40. Learn more about the test on our website: https://lnkd.in/dDiNpaNr #ovariancancer #earlycancerdetection

? New Publication Alert! ? We’re excited that our latest research, titled “Analytical Validation of an Early Detection Pancreatic Cancer Test using 5-Hydroxymethylation Signatures,” has been published in the The Journal of Molecular Diagnostics. ? Following the foundational work by Haan et al. (2023), this publication showcases the rigorous analytical validation of the Avantect Pancreatic Cancer Test. It details key performance metrics, including: > precision > stability > limit of detection (LOD) and compares Avantect to other methylation-based approaches. ? This article underscores Avantect’s reliability and accuracy and adds to the growing evidence that Avantect meets the high-quality standards required for clinical testing. ? ?? Read the full publication here: https://lnkd.in/dQpz5nhe ?? Alternatively, visit our website to learn about the wide range of published research that supports our innovative, #epigenomics based technology: https://lnkd.in/dcadUKsH ? #ClearNoteHealth #PancreaticCancer #EarlyDetection

?? Great energy here at the American Diabetes Association's 84th Scientific Sessions, #ADA2024! ? ?? Stop by the Avantect booth (#1154) to learn more about the increased risk for pancreatic cancer in the new-onset type 2 diabetes #t2dM population. Avantect’s non-invasive test allows for early detection of pancreatic cancer from a simple blood draw. ? Learn more or contact us at https://lnkd.in/g_YvPCdt. ?

?? ?? We are on a mission to help improve awareness around the risks for #pancreaticcancer. Take part in our survey and help spread knowledge. If you’re attending #ADA2024 stop by our booth #1154 and learn more about our non-invasive blood test, the Avantect Pancreatic Test, and how it is enabling a new paradigm of early detection of pancreatic cancer in high risk populations.? ? #ADAscisessions

Are you attending the American Diabetes Association's 84th Scientific Sessions, taking place in Orlando, FL, June 21-24? Don't miss our team at booth #1154! ? ?Are you aware that a new diagnosis of type 2 diabetes significantly increases the risk of #pancreaticcancer??The Avantect Pancreatic Cancer Test is a simple blood test designed to help make earlier diagnosis possible, offering an improved chance for successful treatment and longer survival. ? ?? Visit our team at the event to learn more or contact us at https://lnkd.in/dH3XKJvS ? #ADAscisessions

?? On May 17, 2024, ClearNote Health's CEO Dave Mullarkey traveled to Athens, Greece, solidifying our commercial partnership with GeneKor Medical S.A. to advance the field of early cancer detection. ???Hosted by Nikolaos Tsoulos of Genekor, our discussions centered on the rollout of the Avantect Pancreatic Cancer Test?across multiple EU countries. This innovative diagnostic solution is poised to enhance early detection of pancreatic cancer in key Genekor territories. ? ????During our visit, Dave also engaged with local Key Opinion Leaders to align on the best approaches to integrate this technology into their medical practice and healthcare systems effectively. ? ??This partnership underscores our shared commitment to pioneering advancements in healthcare and to significantly improving patient outcomes through state-of-the-art diagnostics. ? We are inspired by the potential of our collaboration with Genekor and eagerly anticipate the impact our combined efforts will have on transforming cancer care globally. #earlycancerdetection #pancreaticcancer